Latest Breaking News On - Abul abbas - Page 3 : comparemela.com

Share this article Share this article SAN DIEGO, Jan. 25, 2021 /PRNewswire/  NEUVOGEN, an immunoncology company, is pleased to appoint Christian Ottensmeier MD, PhD, FRCP Head of our Scientific Advisory Board ( SAB ). NEUVOGEN s technology platform differs from other immune priming technologies developed for solid tumors by virtue of its unprecedented breadth accompanied by an impressive adjuvant strategy, said Dr. Christian Ottensmeier, Head of the NEUVOGEN Scientific Advisory Board.   Even if only a fraction of the targets primed by their vaccine are translated into primed T cells, the vaccine breadth will still exceed what is possible with other modalities. Ottensmeier continued, NEUVOGEN s preclinical data demonstrates (in vitro) that their proprietary adjuvant strategy is able to prime against self-proteins preferentially expressed by tumors, opening the possibility that the vaccine may overcome peripheral tolerance. Furthermore, NEUVOGEN s preclinical demonstr

United statesSan diegoUniversity of california san franciscoLyudmilaa bazhenovaChristian ottensmeierDavid reardonHideho okadaAbul abbasNeuvogen incUniversity of liverpool school medicineSociety for neuroInstitute of systemsDana farber cancer instituteDepartment of medicineClatterbridge cancer centerParker institute for cancer immunotherapy investigator